A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 52 (planned)
- Started
- Sep 30, 2025
- Main results expected
- Mar 29, 2029
- Fully finished
- Mar 29, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)
Measured over: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)
Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)
Measured over: From first study dose to 21 to 28 days post first dose
Preliminary anti-tumour activity of AZD6621 (PSA Response Rate) (Part B only)
Measured over: Up to 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07192614 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC